In vitro activity of voriconazole against yeast and filamentous fungi, which cause bronchopulmonary and disseminated mycoses in TB patients
https://doi.org/10.54921/2413-0346-2024-12-1-36-41
Abstract
We determined the sensitivity levels to voriconazole of clinical strains of yeasts of the genera Candida (14 species), Cryptococcus (3 species), Geotrichum (one species), Hanseniaspora (one species), Saccharomyces (one species), Saprochaete (one species), Rhodotorula (2 species), Trichosporon (one species) and of filamentous fungi of the genera Acremonium (one species), Alternaria (one species), Aspergillus (12 species), Aureobasidium (one species), Cladosporium (one species), Curvularia (one species), Fusarium (2 species), Paecilomyces (2 species), Penicillium (2 species), Rhizopus (one species), Trichoderma (2 species). Voriconazole activity was high against causative agent of candidiasis, cryptococcosis, aspergillosis, phaeohyphomycosis, rare yeast mycoses (most species), hyalohyphomycosis (most species) and was low against causative agent of rhodotorulosis (Rhodotorula spp.) and zygomycosis (Rhizopus arrhizus).
About the Authors
A. B. Kulko
Moscow Research and Clinical Center for Tuberculosis Control of the Moscow Government Health Department (MRCCTC)
Russian Federation
Russian Federation
S. G. Safonova
Moscow Research and Clinical Center for Tuberculosis Control of the Moscow Government Health Department (MRCCTC)
Russian Federation
Russian Federation
A. I. Isakova
Moscow Research and Clinical Center for Tuberculosis Control of the Moscow Government Health Department (MRCCTC)
Russian Federation
Russian Federation
References
1. Атлас грибковых заболеваний / Под ред.: К.А. Кауфман, Д.Л. Манделла; пер. с англ. под ред. Ю.В. Сергеева. – М.: ГЭОТАР-Медиа. – 2010. – 240 с.
2. Диагностика и лечение микозов / Под ред.: Д.Р. Хоспентала, М. Дж. Риналди; пер. с англ. под ред. Ю.В. Сергеева. – М.: ГЭОТАР-Медиа, 2013. – 448 с.
3. Климко Н.Н. Микозы: диагностика и лечение: Руководство для врачей. – 2-е изд. перераб. и доп. – М.: Ви Джи Групп, 2008. – 336 с.
4. Кулько А.Б. Спектр возбудителей глубоких микозов человека // Онкогематология. – 2012. – № 3. – С. 55-61.
5. Кулько А.Б. Бронхолегочные микозы у больных туберкулезом: состав и свойства возбудителей, лабораторная диагностика: Автореф. дисс. … д-ра биол. наук. – М., 2020. – 49 с.
6. Сергеев А.Ю., Сергеев Ю.В. Грибковые инфекции: Руководство для врачей. – М.: Изд-во Бином, 2008. – 480 с.
7. Cecil J.A., Wenzel, R.P. Voriconazole: a broad-spectrum triazole for the treatment of invasive fungal infections // Expert. Rev. Hematol. – 2009. – Vol. 2, № 3. – P. 237-254.
8. Clinical and Laboratory Standards Institute (CLSI). Reference method for broth dilution antifungal susceptibility testing of yeasts / Fourth Informational Supplement. CLSI document M27-S4. - CLSI: Wayne, PA., 2010. – 29 p.
9. Hoog de G.S., Guarro J., Gene J., Figueras M.J. Atlas of clinical fungi. Electronic version 3.1 – CBS: Reus, 2011. – URL: http://www.clinicalfungi.org/
10. Malani A.N., Kerr L.E., Kauffman C.A. Voriconazole: how to use this antifungal agent and what to expect // Semin. Respir. Crit. Care Med. – 2015. – Vol. 36, № 5. – P. 786-795.
11. Nucci M., Anaissie E. Fusarium infections in immunocompromised patients // Clin. Microbiol. Rev. – 2007. – Vol. 20, № 4. – P. 695-704.
12. Patterson T.F., Thompson G.R., Denning D.W. et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America // Clin. Infect. Dis. – 2016. – Vol. 63, № 4. – P. 433-442.
13. Pfaller M.A., Diekema D.J. Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012 // J. Clin. Microbiol. – 2012. – Vol. 50, № 9. – P. 2846-2856.
14. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs for antifungal agents, version 10.0, 2020.
Review
For citations:
Kulko A.B., Safonova S.G., Isakova A.I. In vitro activity of voriconazole against yeast and filamentous fungi, which cause bronchopulmonary and disseminated mycoses in TB patients. Tuberculosis and socially significant diseases. 2024;12(1):36-41. (In Russ.) https://doi.org/10.54921/2413-0346-2024-12-1-36-41
Views:
110
Email this article 